Quick Answer
GILEAD SCIENCES, INC. reported Stockholders Equity of $22.70 billion for fiscal year 2025.
GILEAD SCIENCES, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $22.70B | +17.4% |
| 2024 | $19.33B | -15.3% |
| 2023 | $22.83B | +7.5% |
| 2022 | $21.24B | +0.8% |
| 2021 | $21.07B | +15.8% |
| 2020 | $18.20B | -19.2% |
| 2019 | $22.52B | +5.3% |
| 2018 | $21.39B | +4.6% |
| 2017 | $20.44B | +8.2% |
| 2016 | $18.89B | +1.9% |
| 2015 | $18.53B | +20.1% |
| 2014 | $15.43B | +35.7% |
| 2013 | $11.37B | +22.2% |
| 2012 | $9.30B | +38.0% |
| 2011 | $6.74B | +14.9% |
| 2010 | $5.86B | -7.9% |
| 2009 | $6.37B | +49.0% |
| 2008 | $4.27B | +13.9% |
| 2007 | $3.75B | +82.9% |
| 2006 | $2.05B | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.54B | +16.6% | +9.5% |
| June 30, 2025 | $19.67B | +7.6% | +2.7% |
| March 31, 2025 | $19.16B | +9.3% | -0.9% |
| December 31, 2024 | $19.33B | -15.3% | +4.6% |
| September 30, 2024 | $18.48B | -17.2% | +1.1% |
| June 30, 2024 | $18.28B | -13.6% | +4.2% |
| March 31, 2024 | $17.54B | -16.5% | -23.2% |
| December 31, 2023 | $22.83B | +7.5% | +2.3% |
- GILEAD SCIENCES, INC. showed an increase of +17.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2006–2025 period, GILEAD SCIENCES, INC.’s stockholders equity has grown by 1006.6% (from $2.05 billion to $22.70 billion).
- The most recent figure is from GILEAD SCIENCES, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: